Showing results (71-80 of 199) with videos related to
Sort By:
Pageof 20
Molecular Therapy. Nucleic Acids|June 4, 2014
Aptamer-facilitated Protection of Oncolytic Virus from Neutralizing AntibodiesDarija Muharemagic, Anna Zamay, Shahrokh M Ghobadloo, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|June 19, 2008
A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replicationRobert E Edge, Theresa J Falls, Christopher W Brown, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|February 27, 2014
Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapyMichelle Cronin, Fabrice Le Boeuf, Carola Murphy, et al.Nature Protocols|May 20, 2024
Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapyShashi Gujar, Jonathan G Pol, Vishnupriyan Kumar, et al.International Journal of Cancer|December 17, 2011
Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infectionFabrice Le Boeuf, Nima Niknejad, Jiahu Wang, et al.Journal of Virology|November 16, 2004
Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKRDionissios Baltzis, Li-Ke Qu, Stavroula Papadopoulou, et al.Cancers|July 30, 2020
Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in TumorigenesisTaha Azad, Reza Rezaei, Abera Surendran, et al.Biochemical and Biophysical Research Communications|August 2, 2003
CHD1 associates with NCoR and histone deacetylase as well as with RNA splicing proteinsHelen H Tai, Margit Geisterfer, John C Bell, et al.Molecular Therapy Oncolytics|September 15, 2016
N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cellsJuan C Corredor, Nicole Redding, Karen Bloté, et al.Human Gene Therapy|September 9, 2004
Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancyBrian D Lichty, David F Stojdl, Rebecca A Taylor, et al.Pageof 20